Aktis Oncology (AKTS) vs MannKind (MNKD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MannKind is the larger company by market cap ($1.06 billion vs $1.01 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKTS | MNKD |
|---|---|---|
| Share price | $18.15 | $3.29 |
| Market cap | $1.01B | $1.06B |
| 1-day change | +2.31% | -3.80% |
| YTD return | — | -41.98% |
| 1-year return | — | -35.99% |
| 5-year return | — | -35.36% |
| Forward P/E | — | 25.80 |
| EPS (TTM) | $-1.74 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.19 | $6.51 |
| 52-week low | $14.72 | $2.23 |
| Distance from 52-week high | -46.91% | -49.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +94.99% | +138.30% |
| Average volume | 364.14K | 4.51M |
| Shares outstanding | 53.75M | 321.54M |
| Employees | 79 | 591 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Aktis Oncology
AKTS stock →Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 79 employees
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 591 employees
AKTS vs MNKD FAQ
Which is bigger, Aktis Oncology or MannKind?
MannKind (MNKD) is larger, with a market capitalization of $1.06B compared with $1.01B for Aktis Oncology (AKTS).
Are Aktis Oncology and MannKind in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.